MENU
+Compare
INZY
Stock ticker: NASDAQ
AS OF
Jun 26 closing price
Price
$4.00
Change
+$0.01 (+0.25%)
Capitalization
258.25M

INZY Inozyme Pharma Forecast, Technical & Fundamental Analysis

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function... Show more

INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for INZY with price predictions
Jun 26, 2025

Momentum Indicator for INZY turns positive, indicating new upward trend

INZY saw its Momentum Indicator move above the 0 level on June 17, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INZY advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 143 cases where INZY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for INZY turned negative on June 05, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INZY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.123) is normal, around the industry mean (16.566). P/E Ratio (0.000) is within average values for comparable stocks, (58.942). INZY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.298). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (254.026).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INZY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

INZY is expected to report earnings to fall 17.18% to -36 cents per share on August 12

Inozyme Pharma INZY Stock Earnings Reports
Q2'25
Est.
$-0.36
Q1'25
Missed
by $0.04
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.05
Q2'24
Missed
by $0.04
The last earnings report on May 14 showed earnings per share of -43 cents, missing the estimate of -40 cents. With 386.44K shares outstanding, the current market capitalization sits at 258.25M.
A.I. Advisor
published General Information

General Information

a company, which engages in the research and development of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
321 Summer Street
Phone
+1 857 330-4340
Employees
59
Web
https://www.inozyme.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MAPIX15.67N/A
N/A
Matthews Asia Dividend Investor
AHGCX10.53N/A
N/A
American Century Heritage C
FMEFX41.18N/A
N/A
Nuveen Small/Mid Cap Growth Opp R6
IUENX27.99N/A
N/A
JPMorgan International Focus R6
FEOPX17.17N/A
N/A
Fidelity Enduring Opportunities

INZY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INZY has been loosely correlated with ACAD. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if INZY jumps, then ACAD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INZY
1D Price
Change %
INZY100%
+0.25%
ACAD - INZY
49%
Loosely correlated
-1.29%
VCYT - INZY
43%
Loosely correlated
+1.36%
KROS - INZY
43%
Loosely correlated
-1.03%
PRME - INZY
42%
Loosely correlated
+9.50%
AURA - INZY
37%
Loosely correlated
-4.26%
More